2020—Subsec. (a)(3)(A). Pub. L. 116–260 inserted “(but not including an individual enrolled solely for coverage of immunosuppressive drugs under section 1395o(b) of this title)” before period at end.
2016—Subsec. (b)(3)(D). Pub. L. 114–198 inserted “, subject to such limits as the Secretary may establish for individuals identified pursuant to section 1395w–104(c)(5) of this title” after “the Secretary”.
2015—Subsec. (b)(1)(B)(ii). Pub. L. 114–10, § 209(b)(2)(B)(ii)(I), inserted “and paragraph (4)” after “paragraph (3)(A)”.
Subsec. (b)(1)(B)(iii). Pub. L. 114–10, § 209(b)(2)(B)(ii)(II), substituted “(E), and (F)” for “and (E)”.
2010—Subsec. (b)(1)(C). Pub. L. 111–148, § 3303(b)(1), inserted “except as provided in subparagraph (D),” after “shall include,”.
Subsec. (b)(1)(D). Pub. L. 111–148, § 3303(b)(2), added subpar. (D).
2006—Subsec. (b)(1)(B)(iii). Pub. L. 109–432 substituted “subparagraphs (B), (C), and (E)” for “subparagraphs (B) and (C)”.
Pub. L. 114–198, title VII, § 704(g)(1),
Pub. L. 111–148, title III, § 3303(c),
Pub. L. 114–198, title VII, § 704(g)(2), (3), “(2) “(A) Not later than “(B) The topics described in this subparagraph are the topics of—“(i) the anticipated impact of drug management programs for at-risk beneficiaries under paragraph (5) of section 1860D–4(c) of the Social Security Act (42 U.S.C. 1395w–104(c)) on cost-sharing and ensuring accessibility to prescription drugs for enrollees in prescription drug plans of PDP sponsors, and enrollees in MA–PD plans, who are at-risk beneficiaries for prescription drug abuse (as defined in subparagraph (C) of such paragraph);“(ii) the use of an expedited appeals process under which such an enrollee may appeal an identification of such enrollee as an at-risk beneficiary for prescription drug abuse under such paragraph (similar to the processes established under the Medicare Advantage program under part C of title XVIII of the Social Security Act [42 U.S.C. 1395w–21 et seq.] that allow an automatic escalation to external review of claims submitted under such part);“(iii) the types of enrollees that should be treated as exempted individuals, as described in subparagraph (C)(ii) of such paragraph;“(iv) the manner in which terms and definitions in such paragraph should be applied, such as the use of clinical appropriateness in determining whether an enrollee is an at-risk beneficiary for prescription drug abuse as defined in subparagraph (C) of such paragraph;“(v) the information to be included in the notices described in subparagraph (B) of such paragraph and the standardization of such notices;“(vi) with respect to a PDP sponsor (or Medicare Advantage organization) that establishes a drug management program for at-risk beneficiaries under such paragraph, the responsibilities of such PDP sponsor (or organization) with respect to the implementation of such program;“(vii) notices for plan enrollees at the point of sale that would explain why an at-risk beneficiary has been prohibited from receiving a prescription at a location outside of the designated pharmacy;“(viii) evidence-based prescribing guidelines for opiates; and“(ix) the sharing of claims data under parts A and B of title XVIII of the Social Security Act [42 U.S.C. 1395c et seq., 1395j et seq.] with PDP sponsors.“(3) Not later than one year after the date of the enactment of this Act [
Pub. L. 111–148, title III, § 3313, “(a) “(1) The Inspector General of the Department of Health and Human Services shall conduct a study of the extent to which formularies used by prescription drug plans and MA–PD plans under part D [42 U.S.C. 1395w–101 et seq.] include drugs commonly used by full-benefit dual eligible individuals (as defined in section 1935(c)(6) of the Social Security Act (42 U.S.C. 1396u–5(c)(6))).“(2) Not later than July 1 of each year (beginning with 2011), the Inspector General shall submit to Congress a report on the study conducted under paragraph (1), together with such recommendations as the Inspector General determines appropriate.“(b) “(1) “(A) The Inspector General of the Department of Health and Human Services shall conduct a study on prices for covered part D drugs under the Medicare prescription drug program under part D of title XVIII of the Social Security Act [42 U.S.C. 1395w–101 et seq.] and for covered outpatient drugs under title XIX [42 U.S.C. 1396 et seq.]. Such study shall include the following:“(i) A comparison, with respect to the 200 most frequently dispensed covered part D drugs under such program and covered outpatient drugs under such title (as determined by the Inspector General based on volume and expenditures), of— “(I) the prices paid for covered part D drugs by PDP sponsors of prescription drug plans and Medicare Advantage organizations offering MA–PD plans; and “(II) the prices paid for covered outpatient drugs by a State plan under title XIX.“(ii) An assessment of— “(I) the financial impact of any discrepancies in such prices on the Federal Government; and “(II) the financial impact of any such discrepancies on enrollees under part D or individuals eligible for medical assistance under a State plan under title XIX.“(B) For purposes of subparagraph (A), the price of a covered part D drug or a covered outpatient drug shall include any rebate or discount under such program or such title, respectively, including any negotiated price concession described in section 1860D–2(d)(1)(B) of the Social Security Act (42 U.S.C. 1395w–102(d)(1)(B)) or rebate under an agreement under section 1927 of the Social Security Act (42 U.S.C. 1396r–8).“(C) Notwithstanding any other provision of law, the Inspector General of the Department of Health and Human Services shall be able to collect any information related to the prices of covered part D drugs under such program and covered outpatient drugs under such title XIX necessary to carry out the comparison under subparagraph (A).“(2) “(A) Not later than “(B) The report submitted under subparagraph (A) shall not include any information that the Inspector General determines is proprietary or is likely to negatively impact the ability of a PDP sponsor or a State plan under title XIX [42 U.S.C. 1396 et seq.] to negotiate prices for covered part D drugs or covered outpatient drugs, respectively.“(3) In this section:“(A) The term ‘covered part D drug’ has the meaning given such term in section 1860D–2(e) of the Social Security Act (42 U.S.C. 1395w–102(e)).“(B) The term ‘covered outpatient drug’ has the meaning given such term in section 1927(k) of such Act (42 U.S.C. 1396r[–8](k)).“(C) MA–PD The term ‘MA–PD plan’ has the meaning given such term in section 1860D–41(a)(9) of such Act (42 U.S.C. 1395w–151(a)(9)).“(D) The term ‘Medicare Advantage organization’ has the meaning given such term in section 1859(a)(1) of such Act (42 U.S.C. 1395w–28)[sic](a)(1)).“(E) PDP The term ‘PDP sponsor’ has the meaning given such term in section 1860D–41(a)(13) of such Act (42 U.S.C. 1395w–151(a)(13)).“(F) The term ‘prescription drug plan’ has the meaning given such term in section 1860D–41(a)(14) of such Act (42 U.S.C. 1395w–151(a)(14)).”
Pub. L. 108–173, title I, § 101(b),
Pub. L. 108–173, title I, § 101(c),
Pub. L. 108–173, title I, § 101(d),
Pub. L. 108–173, title I, § 106, “(a) “(1) There is established, as of the first day of the third month beginning after the date of the enactment of this Act [“(2) For purposes of this section:“(A) The term ‘State pharmaceutical assistance program’ means a program (other than the medicaid program) operated by a State (or under contract with a State) that provides as of the date of the enactment of this Act [“(B) The term ‘program participant’ means a low-income medicare beneficiary who is a participant in a State pharmaceutical assistance program.“(b) The Commission shall include the following:“(1) A representative of each Governor of each State that the Secretary [of Health and Human Services] identifies as operating on a statewide basis a State pharmaceutical assistance program that provides for eligibility and benefits that are comparable or more generous than the low-income assistance eligibility and benefits offered under section 1860D–14 of the Social Security Act [42 U.S.C. 1395w–114].“(2) Representatives from other States that the Secretary identifies have in operation other State pharmaceutical assistance programs, as appointed by the Secretary.“(3) Representatives of organizations that have an inherent interest in program participants or the program itself, as appointed by the Secretary but not to exceed the number of representatives under paragraphs (1) and (2).“(4) Representatives of Medicare Advantage organizations, pharmaceutical benefit managers, and other private health insurance plans, as appointed by the Secretary.“(5) The Secretary (or the Secretary’s designee) and such other members as the Secretary may specify.The Secretary shall designate a member to serve as Chair of the Commission and the Commission shall meet at the call of the Chair.“(c) The Commission shall develop the proposal described in subsection (a) in a manner consistent with the following principles:“(1) Protection of the interests of program participants in a manner that is the least disruptive to such participants and that includes a single point of contact for enrollment and processing of benefits.“(2) Protection of the financial and flexibility interests of States so that States are not financially worse off as a result of the enactment of this title [see Tables for classification].“(3) Principles of medicare modernization under this Act [see Tables for classification].“(d) By not later than “(e) The Secretary shall provide the Commission with the administrative support services necessary for the Commission to carry out its responsibilities under this section.“(f) The Commission shall terminate 30 days after the date of submission of the report under subsection (d).”
Pub. L. 108–173, title I, § 110, “(a) The Federal Trade Commission shall conduct a study of differences in payment amounts for pharmacy services provided to enrollees in group health plans that utilize pharmacy benefit managers. Such study shall include the following:“(1) An assessment of the differences in costs incurred by such enrollees and plans for prescription drugs dispensed by mail-order pharmacies owned by pharmaceutical benefit managers compared to mail-order pharmacies not owned by pharmaceutical benefit managers, and community pharmacies.“(2) Whether such plans are acting in a manner that maximizes competition and results in lower prescription drug prices for enrollees.“(b) Not later than 18 months after the date of the enactment of this Act [“(c) Chapter 35 of title 44, United States Code, shall not apply to the collection of information under subsection (a).”